ZENITH EPIGENETICS CORP has a total of 37 patent applications. Its first patent ever was published in 2013. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are ZENITH EPIGENETICS LTD, NUMEDICUS LTD and IMPACT BIOMEDICINES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 9 | |
#2 | Canada | 7 | |
#3 | China | 7 | |
#4 | Hong Kong | 3 | |
#5 | Republic of Korea | 3 | |
#6 | United States | 3 | |
#7 | Brazil | 1 | |
#8 | Israel | 1 | |
#9 | Mexico | 1 | |
#10 | Singapore | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds | |
#4 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Quinn John Frederick | 27 |
#2 | Duffy Bryan Cordell | 25 |
#3 | Liu Shuang | 24 |
#4 | Young Peter Ronald | 23 |
#5 | Jiang May Xiaowu | 22 |
#6 | Wang Ruifang | 21 |
#7 | Martin Gregory Scott | 20 |
#8 | Wagner Gregory Steven | 17 |
#9 | Zhao He | 12 |
#10 | Brown Samuel David | 7 |
Publication | Filing date | Title |
---|---|---|
WO2016097870A1 | Substituted bicyclic compounds as bromodomain inhibitors | |
CN107406438A | The inhibitor of bromine domain | |
CN107207474A | Substituted heterocycle is used as bromine domain inhibitor | |
WO2015015318A2 | Novel quinazolinones as bromodomain inhibitors |